| COMMENTARY |
|
| Year : 2020 | Volume
: 4
| Issue : 2 | Page : 226-229 |
|
|
COVID-19: Neuropsychiatric manifestations and psychopharmacology
Harpreet Singh Dhillon1, Shibu Sasidharan2, Gurpreet Kaur Dhillon3, Vijay Singh2, M Babitha4
1 Department of Psychiatry, Level III Hospital, Goma, DRC
2 Department of Anaesthesiology and Critical Care, Level III Hospital, Goma, DRC
3 Department of Paediatrics, 166 Military Hospital, Jammu, Jammu and Kashmir, India
4 Consultant Radiologist, Ojas Hospital, Panchkula, Haryana, India
Correspondence Address:
Dr. Harpreet Singh Dhillon
Department of Psychiatry, Level III Hospital, Goma
DRC
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/aip.aip_78_20
|
|
|
The COVID-19 pandemic has emerged as one of the major global health crises of recent times. It has posed adverse consequences for people with mental illnesses with its potential to infect patients with existing psychiatric disorders on psychotropic drugs and additionally, spawning psychiatric symptoms in patients infected with COVID-19. To add to the miseries, there have been a multitude of experimental treatments in the form of antivirals, immune-modulators, corticosteroids, etc., which can have serious interactions with psychotropic drugs. In this review, we intend to provide recommendations for pharmacotherapy to address the neuropsychiatric morbidity in COVID-19 patients.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
